Posted by Defense World Staff on Jul 1st, 2024
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 127.43% from the stock’s current price.
Other research analysts have also recently issued research reports about the company. Oppenheimer started coverage on MoonLake Immunotherapeutics in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $104.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Monday, June 10th. The Goldman Sachs Group began coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, April 2nd. They set a “neutral” rating and a $62.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $92.00 target price on shares of MoonLake Immunotherapeutics in a report on Wednesday, March 13th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.00.
Check Out Our Latest Stock Analysis on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Price Performance
MLTX opened at $43.97 on Monday. The business has a 50 day simple moving average of $41.40 and a 200-day simple moving average of $49.35. MoonLake Immunotherapeutics has a 12 month low of $35.11 and a 12 month high of $64.98. The stock has a market capitalization of $2.81 billion, a P/E ratio of -58.63 and a beta of 1.25.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last issued its earnings results on Sunday, May 12th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Research analysts anticipate that MoonLake Immunotherapeutics will post -1.21 EPS for the current year.
Institutional Trading of MoonLake Immunotherapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of MLTX. California State Teachers Retirement System lifted its holdings in MoonLake Immunotherapeutics by 2.7% during the 1st quarter. California State Teachers Retirement System now owns 16,366 shares of the company’s stock worth $822,000 after buying an additional 429 shares during the last quarter. Quarry LP acquired a new position in MoonLake Immunotherapeutics in the fourth quarter worth $51,000. PNC Financial Services Group Inc. increased its stake in MoonLake Immunotherapeutics by 50.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,147 shares of the company’s stock valued at $371,000 after purchasing an additional 2,067 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter worth $202,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter worth $217,000. 93.85% of the stock is owned by institutional investors.
MoonLake Immunotherapeutics Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Recommended Stories
- Five stocks we like better than MoonLake Immunotherapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Stocks Upgraded by Analysts: Home Depot, U.S. Steel, Alcoa
- How Technical Indicators Can Help You Find Oversold Stocks
- NVIDIA and TSM Stock: Is Semiconductor Sector Momentum Slowing?
- How to Calculate Inflation Rate
- Palo Alto Networks Stock Gains AI-Powered Cybersecurity Solutions
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
Kowal Investment Group LLC Acquires 100 Shares of Mastercard Incorporated
Hexagon Capital Partners LLC Sells 616 Shares of Air Lease Co.
Talbot Financial LLC Has $16.56 Million Holdings in Chevron Co.
